We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
Diane Paskiet, Director Scientific Affairs, will provide an update on the PQRI-PODP working group at the Smithers Rapra Extractables and Leachables conference in Barcelona, Spain on November 10-12, 2014.
Diane serves as chair of the Product Quality research Institute (PQRI) Parenteral and Ophthalmic Drug Product Leachables and Extractables Working Group and will present the objectives of the group and application of Thresholds and Best Practices to Prefilled Syringe components at a session on Tuesday, November 11. PQRI extractables data from common packaging materials and toxicological assessments will also be displayed.
The conference will include presentations on:
To learn more or register to attend, visit: http://www.eandl-conference.com/extractables-and-leachables.aspx
A key element of West’s commitment to a safe and efficient delivery of drug products is staying abreast of industry developments, and being prepared to help customers navigate them. Recently Dow Corning introduced a new product - Dow Corning® 366 35% Dimethicone NF Emulsion.
One of the most important aspects for choosing container closure system for parenteral drug products is to ensure an ideal fit between all components to maintain product sterility.
At West, we pride ourselves for our passion for our customers. We work hard to be by the side of their journey to ultimately create a healthier world. Our customers, both big and small, work every day to help patients with various diseases, syndromes, and conditions live a better life. We consider the success of our customers to be our success as well.
Recently, there has been increased scrutiny from regulatory authorities to quantify and qualify subvisible particles in biopharmaceutical products. Such particles, which can cause a protein to denature, are of concern to pharmaceutical manufacturers since they can affect the efficacy of the drug product. As regulatory bodies continue to raise the bar on quality, industry is looking for “zero defect” and particle free components as well as a way to minimize quality variation.
We are pleased to announce that Jennifer Ogden, Director, Global Accounts, has been recognized by the HealthCare Businesswomen’s Association (HBA) as West’s 2015 Rising Star. Jenn is a leader among the sales force and is responsible for developing and driving the execution of account strategies with West’s global biotech customers.
English
Chinese
